Chemotherapy Extravasation — Part 3: Follow-Up Care, Documentation, Legal Considerations, and Staff Education

1. Surgical Consultation Criteria

Surgical consultation should be obtained for extravasation injuries that meet any of the following criteria. Timely surgical evaluation is essential because delayed intervention increases the risk of permanent tissue damage, functional impairment, and complex wound management.¹²³

1.1 Indications for Immediate Surgical Consultation (Within 24–72 Hours)

1.2 Indications for Surgical Consultation During Follow-Up

1.3 Surgical Management Options

The specific surgical intervention depends on the severity and extent of the injury:¹³

2. Wound Assessment and Grading

Standardized wound assessment at each follow-up visit allows objective tracking of extravasation injury progression or resolution. Several grading systems have been described; the following is adapted from published classifications used by oncology nursing standards bodies and expert panels.¹⁴⁵

2.1 Extravasation Injury Grading Scale

2.2 Wound Assessment Parameters

At each follow-up visit, the following parameters should be assessed and documented:⁴⁵

3. Patient Follow-Up Protocols

3.1 Follow-Up Schedule

The follow-up schedule depends on the severity of the extravasation and the agent involved. The following represents the minimum recommended follow-up framework, synthesized from multiple guideline sources:¹²⁵⁶

For vesicant extravasation:

For irritant extravasation:

For non-vesicant extravasation:

3.2 Decision to Continue or Delay Chemotherapy

The decision to continue the planned chemotherapy course after an extravasation event requires clinical judgment:²⁵

1. Same treatment day: If the extravasation is recognized early, the remaining dose of the extravasated agent may be administered through a new intravenous access site (preferably in a different extremity) if the patient is clinically stable and the treating physician determines it is safe to proceed
2. Subsequent cycles: Vesicant extravasation does not necessarily contraindicate future administration of the same agent; however:
   • Central venous access should be strongly considered for subsequent cycles
   • The patient should be assessed for unresolved tissue injury before the next cycle
   • If the extravasation resulted in significant tissue damage, a multidisciplinary discussion about risk-benefit of continuing the specific agent is warranted
3. Dexrazoxane interaction with chemotherapy: Dexrazoxane may interfere with the efficacy of certain chemotherapy agents (particularly topoisomerase II inhibitors). Discuss with the treating oncologist whether to modify the timing of the next chemotherapy cycle

4. Peripheral vs. Central Line Extravasation: Management Differences

4.1 Peripheral Extravasation

Peripheral intravenous extravasation is the most common type and is the primary focus of the management algorithms described in Part 2. Key characteristics include:¹²

• The extravasated drug enters the subcutaneous tissue of the extremity
• The affected area is typically visible, palpable, and accessible for examination and treatment
• Antidote administration (subcutaneous injection) is straightforward
• Thermal application is easily applied
• The volume of extravasated drug is usually limited by the recognition of local signs

4.2 Central Venous Access Device Extravasation

CVAD extravasation presents unique challenges and requires modified management approaches:²⁷⁸

Causes of CVAD extravasation:

Management of CVAD extravasation:

1. Stop the infusion immediately — same as peripheral extravasation
2. Attempt to aspirate through the device if possible
3. Assess the extent of extravasation:
   • For port-pocket or subcutaneous tunnel extravasation: manage similarly to peripheral extravasation with antidote and thermal application if the affected area is accessible
   • For mediastinal or pleural extravasation: this is a medical emergency. Obtain urgent imaging (chest X-ray, CT) and surgical consultation. Management may include chest tube placement, mediastinal drainage, or emergent surgery
4. Do NOT remove the CVAD until physician evaluation (the device may need to be removed surgically or under fluoroscopic guidance, and the tract may need to be assessed)
5. Obtain imaging:
   • Chest X-ray to confirm catheter position and assess for pleural effusion, mediastinal widening, or subcutaneous fluid collection
   • CT scan if mediastinal or pleural extravasation is suspected
   • Dye study (contrast injection through the device under fluoroscopy) to confirm catheter integrity if the device is intact and patency is uncertain
6. Antidote administration for CVAD extravasation into the chest wall or port pocket is more complex:
   • Dexrazoxane can be administered intravenously through a peripheral line in a different extremity
   • Subcutaneous antidotes (hyaluronidase, sodium thiosulfate) may be injected around the affected area if the extravasation site is accessible and in the subcutaneous tissue
   • For mediastinal or pleural extravasation, subcutaneous antidotes are not applicable; systemic antidotes (dexrazoxane) and surgical intervention are the primary management options
7. Device removal or salvage:
   • If the device is fractured, disconnected, or irreparably damaged, it must be removed
   • If malposition is the cause, the catheter may be repositioned under fluoroscopic guidance if the catheter is intact and no tissue damage has occurred
   • Decision to remove or salvage the device should be made in consultation with the vascular access team, surgeon, or interventional radiologist

5. Documentation Requirements

Thorough, standardized documentation of extravasation events is essential for patient safety, continuity of care, quality improvement, and medicolegal protection. The expert panels and the infusion therapy standards body recommend that the following elements be documented in the medical record:¹⁵⁶⁸

5.1 Minimum Documentation Elements

5.2 Extravasation Incident Report

In addition to medical record documentation, an institutional incident or adverse event report should be completed per institutional policy. This report typically includes:⁵⁶

• A narrative description of the event
• Contributing factors identified
• Immediate actions taken
• Patient outcome at the time of reporting
• Recommendations for prevention of future events

6. Incident Reporting and Quality Improvement

6.1 Internal Reporting

All extravasation events should be reported through the institution’s adverse event or patient safety reporting system. Extravasation events involving vesicant agents should be classified as a significant adverse event and should trigger a formal review.⁵⁶

6.2 Root Cause Analysis

For serious extravasation events (those resulting in tissue necrosis, surgical intervention, or prolonged morbidity), a structured review or root cause analysis should be conducted to identify contributing factors and opportunities for system improvement. Factors to evaluate include:

6.3 Quality Metrics

Institutions should track the following quality metrics related to chemotherapy extravasation:⁵⁶

• Extravasation rate (number of events per total number of chemotherapy administrations)
• Time from detection to antidote administration (for vesicant extravasations)
• Percentage of extravasation events with complete documentation
• Surgical intervention rate following extravasation
• Patient injury severity outcomes (using the grading scale in Section 2.1)
• Staff competency validation completion rates
• Extravasation kit availability and readiness audit results

7. Legal and Medicolegal Considerations

Chemotherapy extravasation is recognized in the medicolegal literature as a potential source of malpractice claims. Claims may arise from alleged failure in prevention, delayed detection, inadequate management, or insufficient follow-up. The following considerations are derived from published legal analyses and expert panel recommendations:³⁵⁹

7.1 Standard of Care

The standard of care for chemotherapy administration and extravasation management is defined by published guidelines, professional standards of practice (including those of the oncology nursing professional societies and the infusion therapy standards body), institutional policies, and prevailing community practice. Clinicians are expected to:

1. Assess and document patient risk factors before vesicant administration
2. Select appropriate vascular access based on drug classification, patient factors, and treatment plan
3. Follow institutional protocol for vein selection, catheter placement, and infusion technique
4. Monitor the infusion site at intervals consistent with published standards and institutional policy
5. Recognize extravasation promptly and initiate management without delay
6. Administer the appropriate antidote within the recommended time window
7. Document all aspects of the event, management, and follow-up
8. Arrange and complete appropriate follow-up assessments

7.2 Documentation as Legal Protection

Thorough, contemporaneous documentation is the most important legal protection for clinicians involved in an extravasation event. The medical record should demonstrate:

• That prevention measures were in place and followed
• That the site was monitored at appropriate intervals
• That the extravasation was detected and managed promptly
• That the appropriate antidote was administered within the recommended time frame
• That the patient was informed and that follow-up was arranged
• That clinical judgment was exercised at each decision point

7.3 Informed Consent

Expert panels and the chemotherapy safety standards body recommend that informed consent for chemotherapy treatment include discussion of the risk of extravasation, particularly when vesicant agents are prescribed.⁵⁶ The consent discussion and documentation should include:

• The risk of extravasation as a known complication of intravenous chemotherapy
• The potential consequences of extravasation (tissue damage, need for surgical intervention)
• Measures taken to prevent extravasation
• The importance of the patient’s role in reporting symptoms promptly
• For patients declining recommended central venous access when it is clinically indicated for vesicant administration: documentation that the patient was informed of the increased risk of peripheral vesicant administration and chose to proceed

7.4 Regulatory Reporting

Depending on jurisdiction and institutional requirements, extravasation events may be subject to mandatory reporting requirements:

• Serious adverse events resulting in significant patient harm may require reporting to state health departments or patient safety organizations
• Events involving medical device malfunction (e.g., catheter fracture, port failure) may be reportable to the relevant medical device regulatory authority (e.g., the FDA’s MedWatch program in the United States)
• Institutional accreditation organizations may require documentation of the event and subsequent quality review

8. Staff Education and Competency Requirements

The chemotherapy safety standards require that all healthcare professionals involved in the administration of antineoplastic agents demonstrate competency in extravasation prevention, recognition, and management.⁵⁶⁸

8.1 Initial Education Requirements

All nurses and other healthcare professionals who administer intravenous chemotherapy must complete education covering the following topics before independently administering vesicant agents:

8.2 Competency Validation

Initial competency should be validated through:⁵⁶

1. Didactic education — completion of a structured educational program covering all topics listed above, with a post-test demonstrating knowledge mastery (minimum passing score per institutional policy)
2. Clinical demonstration — observed demonstration of:
   • Vein assessment and catheter placement
   • Blood return verification
   • Vesicant administration technique (IV push and continuous infusion)
   • Extravasation management steps (using simulation or skills lab)
   • Antidote preparation and administration technique
   • Extravasation kit location and contents review
3. Preceptorship — administration of vesicant agents under the direct supervision of a competency-validated preceptor for a defined number of administrations before independent practice

8.3 Ongoing Competency

Competency should be re-validated at defined intervals (typically annually or biennially) through:⁵⁶

8.4 Pharmacy Education

Pharmacists involved in the preparation of antineoplastic agents should also receive education on:⁵

• Drug classification by vesicant, irritant, and non-vesicant potential
• Concentration-dependent classification changes
• Antidote preparation, storage, and stability (particularly dexrazoxane reconstitution and stability)
• Institutional protocols for urgent antidote dispensing when extravasation occurs
• Communication pathways for rapid notification when a vesicant extravasation is reported

9. Institutional Protocol Development

9.1 Essential Protocol Components

The guidelines committee, the chemotherapy safety standards, and the supportive care expert group all recommend that every institution administering cytotoxic agents maintain a written, regularly updated extravasation prevention and management protocol. The protocol should include:¹⁵⁶⁸

1. Institutional drug classification list — an up-to-date list of all antineoplastic agents on the formulary classified as vesicant, irritant, or non-vesicant, reviewed and updated at least annually
2. Vascular access decision algorithm — criteria for recommending central venous access based on agent classification, patient risk factors, and treatment plan
3. Administration standards — specific procedures for vesicant administration including pre-administration assessment, monitoring frequency, and post-administration care
4. Extravasation management algorithm — step-by-step management instructions organized by agent class, including antidote selection, dosing, and thermal management
5. Extravasation kit contents and maintenance — list of all required kit components; process for regular checking and restocking; expiration date monitoring for antidotes
6. Documentation forms — standardized extravasation documentation forms or electronic health record templates
7. Notification cascade — who must be notified (physician, pharmacist, charge nurse, risk management) and in what order
8. Follow-up protocol — minimum follow-up schedule by extravasation severity
9. Incident reporting process — process for completing adverse event reports and triggering quality review
10. Education and competency requirements — requirements for initial and ongoing competency validation

9.2 Protocol Review and Update

Institutional extravasation protocols should be reviewed and updated:⁵

• At minimum annually, or sooner if:
  • New antineoplastic agents are added to the formulary
  • New evidence regarding antidotes or management is published
  • Institutional review of an extravasation event identifies protocol deficiencies
  • Regulatory or accreditation requirements change
• The protocol review process should include representation from oncology nursing, pharmacy, oncology medical staff, vascular access teams, and quality/patient safety

9.3 Extravasation Kit Maintenance

10. Summary of Key Recommendations

The following table summarizes the critical time-sensitive actions required for each vesicant agent class:

11. Algorithm: Complete Extravasation Management Decision Pathway

STEP 1 — Extravasation suspected or confirmed

• Stop infusion immediately
• Do NOT remove catheter yet
• Do NOT flush the line

STEP 2 — Aspirate

• Attempt to withdraw residual drug through catheter (typically 0.1–3 mL)
• Then remove catheter
• Outline affected area with skin marker

STEP 3 — Identify the agent

• Vesicant (DNA-binding) → Go to STEP 4A
• Vesicant (non-DNA-binding: vinca alkaloid/taxane) → Go to STEP 4B
• Irritant → Go to STEP 4C
• Non-vesicant → Go to STEP 4D

STEP 4A — DNA-binding vesicant

• Is the agent an anthracycline?
  • YES: Administer dexrazoxane IV within 6 hours (if available). Do NOT apply cold during dexrazoxane course. Do NOT use DMSO with dexrazoxane.
  • If dexrazoxane unavailable: Apply DMSO 99% topically q8h × 7–14 days + cold compresses 15–20 min QID × 24–72 hours
• Is the agent mechlorethamine?
  • YES: Inject sodium thiosulfate 1/6 M SC immediately + cold compresses
• Is the agent mitomycin C or dactinomycin?
  • YES: Apply DMSO 99% topically q8h × 7–14 days + cold compresses
• Other DNA-binding vesicant (trabectedin): Cold compresses; no specific antidote
• Elevate extremity; surgical consultation per criteria (Section 1)
• Follow up at 24 hours

STEP 4B — Non-DNA-binding vesicant (vinca alkaloid or taxane)

• Inject hyaluronidase 150–300 units SC around extravasation site
• Apply warm compresses 15–20 min QID × 24–72 hours
• Elevate extremity
• Follow up at 24 hours

STEP 4C — Irritant agent

• Apply cold compresses 15–20 min QID × 24–48 hours
• Elevate extremity
• Consider agent-specific measures (see Part 2, Section 5)
• Follow up at 24–48 hours if symptoms persist

STEP 4D — Non-vesicant agent

• Apply cold or warm compresses for comfort
• Elevate extremity
• Restart infusion in a different vein if treatment must continue
• Monitor at 24 hours; phone follow-up generally sufficient

STEP 5 — All extravasation events

• Notify physician/oncologist
• Complete extravasation documentation
• Complete incident report per institutional policy
• Provide patient with written discharge instructions
• Arrange follow-up per severity-based schedule (Section 3.1)

References